Manjyot K Nanhwan
Overview
Explore the profile of Manjyot K Nanhwan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
162
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chen Y, Chen H, Birnbaum Y, Nanhwan M, Bajaj M, Ye Y, et al.
Diab Vasc Dis Res
. 2017 Jan;
14(2):152-162.
PMID: 28111985
Purpose: To assess the effects of Aleglitazar on hyperglycaemia-induced apoptosis. Methods: We incubated human cardiomyocytes, cardiomyocytes from cardiac-specific peroxisome proliferator-activated receptor-γ knockout or wild-type mice in normoglycaemic or hyperglycaemic conditions...
2.
Qian J, Chen H, Birnbaum Y, Nanhwan M, Bajaj M, Ye Y
Cardiovasc Drugs Ther
. 2016 Feb;
30(2):129-41.
PMID: 26861490
Purpose: To evaluate whether aleglitazar (Ale), a dual PPARα/γ agonist, has additive effects on myocardial protection against ischemia-reperfusion injury. Methods: Human cardiomyocytes (HCMs), cardiomyocytes from cardiac-specific PPARγ knockout (MCM-PPARγ (CKO)...
3.
Ye Y, Birnbaum G, Perez-Polo J, Nanhwan M, Nylander S, Birnbaum Y
Arterioscler Thromb Vasc Biol
. 2015 Jun;
35(8):1805-14.
PMID: 26044583
Objective: In addition to P2Y12 receptor antagonism, ticagrelor inhibits adenosine cell uptake. Prior data show that 7-day pretreatment with ticagrelor limits infarct size. We explored the acute effects of ticagrelor...
4.
Birnbaum Y, Nanhwan M, Ling S, Perez-Polo J, Ye Y, Bajaj M
Cardiovasc Drugs Ther
. 2014 Aug;
28(5):447-57.
PMID: 25106875
Purpose: Statins increase the incidence of new onset diabetes. Prolonged statin therapy upregulates PTEN expression. PTEN levels are also elevated in diabetic animals. Activation of protein kinase A by cAMP...
5.
Nanhwan M, Ling S, Kodakandla M, Nylander S, Ye Y, Birnbaum Y
Arterioscler Thromb Vasc Biol
. 2014 Jul;
34(9):2078-85.
PMID: 25012137
Objective: In a phase III clinical trial (PLATelet inhibition and patient Outcomes, PLATO), ticagrelor provided better clinical outcomes than clopidogrel in patients with acute coronary syndromes. In addition to P2Y12-receptor...
6.
Ling S, Birnbaum Y, Nanhwan M, Thomas B, Bajaj M, Ye Y
Cell Signal
. 2013 Sep;
25(12):2840-7.
PMID: 24018047
Both HIF1α (hypoxia-inducible factor alpha) and VEGF (vascular endothelial growth factor) are implicated in the pathogenesis of diabetic retinopathy (DR). Competitive endogenous RNAs (ceRNAs) are messenger RNA (mRNA) molecules that...
7.
Ling S, Birnbaum Y, Nanhwan M, Thomas B, Bajaj M, Li Y, et al.
Basic Res Cardiol
. 2013 May;
108(3):352.
PMID: 23636253
Competitive endogenous RNAs (ceRNAs) regulate mRNA transcripts containing common microRNA (miRNA) recognition elements (MREs) through sequestration of shared miRNAs. Interactions of ceRNA have been demonstrated in cancerous cells. However, a...